Alder BioPharmaceuticals of Bothell priced its initial public offering of stock at $10, below the expected range of $13 to $15.
Alder shares, listed on Nasdaq under the ticker ALDR, closed up 3 cents at $10.03 in their trading debut Thursday.
The offering raised $80 million before expenses for the biotech company, which is testing two drug candidates it developed — one to prevent migraines and one to treat rheumatoid arthritis and psoriatic arthritis.
Alder filed its IPO plans in mid-March, when biotech deals were booming. But investor enthusiasm for the sector has cooled, with the Nasdaq biotechnology index down more than 14 percent since March 18.
- With death on table, McEnroe jury's friendships crumbled
- Microsoft employees -- past and present -- look back over the years
- To retire at 55 takes big savings
- Salary cap expert Joel Corry with another look at Russell Wilson's contract
- No time to eat in Silicon Valley, so techies chug their protein